SBI Healthcare Opportunities Fund
Direct · GrowthAI Summary
SBI Healthcare Opportunities Fund has delivered strong SIP returns, with XIRR of 20.8% over 3Y, 18.61% over 5Y, and 17.38% over 10Y. Against the NIFTY 50, the fund has generated substantial alpha, including 18.16% over 3Y and 13.11% over 5Y, while its lump-sum CAGR of 24.6% (3Y) far exceeded the benchmark's 6.4%. It has also outpaced its category average SIP XIRR across most periods, including 20.8% vs 16.16% over 3Y and 17.38% vs 16.43% over 10Y.
The fund exhibits a low beta of roughly 0.55 versus NIFTY 50 across all periods, meaning it moves independently of broad market swings, which is typical of a defensive sector fund. Downside capture is consistently below upside capture (for example, 69.97% upside vs 44.72% downside over 3Y), indicating favorable asymmetric behavior relative to the benchmark. The fund has experienced 6 drawdown events exceeding 10%, and a Calmar ratio of roughly 0.48 to 0.66 across periods reflects meaningful drawdown risk despite the defensive sector tilt.
The portfolio is a concentrated healthcare bet, with Pharmaceuticals & Biotechnology at 60.3% and Healthcare Services at 25.6% of NAV. Sun Pharma (11.14%) and Divi's Labs (7.91%) are the largest positions, and the top 10 holdings together account for roughly 51.8% of the 34-stock portfolio. This focused structure amplifies both the fund's alpha potential and its sector-specific risk.
The fund consistently beats the category average SIP XIRR across horizons: 18.16% vs 10.55% (1Y), 20.8% vs 16.16% (3Y), and 17.44% vs 15.77% (12Y). Rolling return means of 15.17% (1Y) and 20.05% (3Y) show that lump-sum investors have also been well compensated over longer windows. This sustained outperformance versus peers suggests skilled navigation of the healthcare theme over multiple market cycles.
This fund suits investors with high risk tolerance who understand sector concentration risk and want tactical exposure to the healthcare and Pharma theme, ideally as a satellite holding of 5-10% of their overall portfolio rather than a core holding. A time horizon of at least 5-7 years is advisable, given the calendar-year volatility (returns ranged from -13.11% in 2016 to +67.14% in 2020). Investors should be comfortable with extended underperformance phases when the sector is out of favor.
- Consistent outperformance versus both the NIFTY 50 benchmark (alpha of 13.11% to 20.26% over 1Y-5Y periods) and the category average SIP XIRR across all time horizons
- Favorable capture profile with low downside capture (38.74% to 56.68%) relative to upside capture (61.4% to 69.97%), aided by a low beta near 0.55
- Strong recovery behavior after drawdowns, with recovery from the maximum drawdown completed in 91 days
- Heavy sector concentration with 85.9% in just two sectors (Pharma 60.3%, Healthcare Services 25.6%), exposing investors to regulatory, pricing, and US FDA-related sector shocks
- A long maximum drawdown duration of 1613 days and 6 drawdown events exceeding 10% highlight the potential for prolonged underperformance phases typical of thematic funds
Generated on 03-11-2026, 4:36 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.65 L | 20.9% | -28.2% | 108.4% |
| 3 Years | ₹36.00 L | ₹46.00 L | 16.1% | -13.3% | 42.0% |
| 5 Years | ₹60.00 L | ₹93.26 L | 15.4% | -7.4% | 31.4% |
| 7 Years | ₹84.00 L | ₹1.52 Cr | 17.4% | -0.8% | 27.5% |
| 10 Years | ₹1.20 Cr | ₹3.07 Cr | 17.4% | 11.3% | 21.3% |
| 12 Years | ₹1.44 Cr | ₹4.41 Cr | 17.5% | 15.4% | 19.6% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 20.9% | 14.3% | 10.3% | +6.6% |
| 3 Years | 16.1% | 11.0% | 16.2% | +5.1% |
| 5 Years | 15.4% | 10.4% | 17.4% | +5.1% |
| 7 Years | 17.4% | 10.6% | 16.6% | +6.8% |
| 10 Years | 17.4% | 11.4% | 16.4% | +5.9% |
| 12 Years | 17.5% | 11.3% | 15.8% | +6.1% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 20.2% | 14.4% | -18.2% | 91.7% | 0.54 | 1.83 | 71% | — | — |
| 3 Years | 16.4% | 21.1% | -8.9% | 36.5% | 0.82 | 1.99 | 81% | — | — |
| 5 Years | 14.7% | 13.4% | -4.2% | 33.3% | 1.00 | 4.47 | 99% | — | — |
| 10 Years | 14.8% | 14.9% | 11.1% | 17.6% | 5.48 | — | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +18.77 | 0.54 | 64.7% | 38.4% | 17.7% | -7.6% |
| 3 Years | +17.51 | 0.55 | 69.1% | 44.7% | 24.5% | 7.4% |
| 5 Years | +12.92 | 0.54 | 64.0% | 45.5% | 19.1% | 6.0% |
| 7 Years | +16.19 | 0.52 | 61.0% | 41.7% | 24.7% | 10.4% |
| 10 Years | +6.14 | 0.55 | 61.9% | 51.9% | 15.0% | 10.9% |
| 12 Years | +6.63 | 0.59 | 67.1% | 56.7% | 14.7% | 9.2% |
| 15 Years | +8.20 | 0.57 | 65.8% | 52.8% | 16.5% | 9.6% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Sun Pharmaceutical Industries Ltd. | 11.14% |
| 2 | Divi's Laboratories Ltd. | 7.91% |
| 3 | Acutaas Chemicals Ltd. | 5.03% |
| 4 | Apollo Hospitals Enterprise Ltd. | 4.45% |
| 5 | Torrent Pharmaceuticals Ltd. | 4.42% |
| 6 | Cipla Ltd. | 4.40% |
| 7 | Laurus Labs Ltd. | 4.05% |
| 8 | Max Healthcare Institute Ltd. | 3.80% |
| 9 | Aurobindo Pharma Ltd. | 3.42% |
| 10 | Aster DM Quality Care Ltd. | 3.21% |